RATIONALE: Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about their responsiveness to this lipid mediator. OBJECTIVES: To compare responses to PGE2 in normal, usual interstitial pneumonia (UIP), and other diffuse parenchymal lung disease (DPLD) fibroblasts. METHODS: Fibroblasts were grown in vitro from well characterized control (n = 7), UIP (n = 17), or other DPLD (n = 13) lung tissue. The effects of PGE2 on fibroblast proliferation and collagen expression were determined. MEASUREMENTS AND MAIN RESULTS: Only 3 of 12 UIP fibroblast lines exhibited PGE2-mediated inhibition of both collagen synthesis and cell proliferation, as opposed to 6 of 6 nonfibrotic control cell lines. The degree of PGE2 resistance in DPLD fibroblasts was quite variable, with UIP cells exhibiting the greatest degree of resistance to PGE2, whereas other DPLD fibroblasts manifested a degree of resistance intermediate to control and UIP. The resistance to suppression of collagen expression correlated with worse lung function. Molecular mechanisms for resistance included altered E prostanoid receptor profiles and diminished expression of the downstream kinase, protein kinase A. CONCLUSIONS: The recognition that UIP fibroblasts manifest variable refractoriness to PGE2 suppression sheds new light on the activation phenotype of these cells and on the pathogenesis of fibrotic lung disease.
RATIONALE: Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about their responsiveness to this lipid mediator. OBJECTIVES: To compare responses to PGE2 in normal, usual interstitial pneumonia (UIP), and other diffuse parenchymal lung disease (DPLD) fibroblasts. METHODS: Fibroblasts were grown in vitro from well characterized control (n = 7), UIP (n = 17), or other DPLD (n = 13) lung tissue. The effects of PGE2 on fibroblast proliferation and collagen expression were determined. MEASUREMENTS AND MAIN RESULTS: Only 3 of 12 UIP fibroblast lines exhibited PGE2-mediated inhibition of both collagen synthesis and cell proliferation, as opposed to 6 of 6 nonfibrotic control cell lines. The degree of PGE2 resistance in DPLD fibroblasts was quite variable, with UIP cells exhibiting the greatest degree of resistance to PGE2, whereas other DPLD fibroblasts manifested a degree of resistance intermediate to control and UIP. The resistance to suppression of collagen expression correlated with worse lung function. Molecular mechanisms for resistance included altered E prostanoid receptor profiles and diminished expression of the downstream kinase, protein kinase A. CONCLUSIONS: The recognition that UIP fibroblasts manifest variable refractoriness to PGE2 suppression sheds new light on the activation phenotype of these cells and on the pathogenesis of fibrotic lung disease.
Authors: K R Flaherty; W D Travis; T V Colby; G B Toews; E A Kazerooni; B H Gross; A Jain; R L Strawderman; A Flint; J P Lynch; F J Martinez Journal: Am J Respir Crit Care Med Date: 2001-11-01 Impact factor: 21.405
Authors: T Kohyama; R F Ertl; V Valenti; J Spurzem; M Kawamoto; Y Nakamura; T Veys; L Allegra; D Romberger; S I Rennard Journal: Am J Physiol Lung Cell Mol Physiol Date: 2001-11 Impact factor: 5.464
Authors: R Stratton; X Shiwen; G Martini; A Holmes; A Leask; T Haberberger; G R Martin; C M Black; D Abraham Journal: J Clin Invest Date: 2001-07 Impact factor: 14.808
Authors: C Vancheri; M A Sortino; V Tomaselli; C Mastruzzo; F Condorelli; G Bellistrí; M P Pistorio; P L Canonico; N Crimi Journal: Am J Respir Cell Mol Biol Date: 2000-05 Impact factor: 6.914
Authors: K R Flaherty; G B Toews; W D Travis; T V Colby; E A Kazerooni; B H Gross; A Jain; R L Strawderman; R Paine; A Flint; J P Lynch; F J Martinez Journal: Eur Respir J Date: 2002-02 Impact factor: 16.671
Authors: Jill E Kolodsick; Marc Peters-Golden; Jose Larios; Galen B Toews; Victor J Thannickal; Bethany B Moore Journal: Am J Respir Cell Mol Biol Date: 2003-05-08 Impact factor: 6.914
Authors: Kristy A Bauman; Scott H Wettlaufer; Katsuhide Okunishi; Kevin M Vannella; Joshua S Stoolman; Steven K Huang; Anthony J Courey; Eric S White; Cory M Hogaboam; Richard H Simon; Galen B Toews; Thomas H Sisson; Bethany B Moore; Marc Peters-Golden Journal: J Clin Invest Date: 2010-05-24 Impact factor: 14.808
Authors: Steven K Huang; Anne M Scruggs; Jake Donaghy; Richard C McEachin; Aaron S Fisher; Bruce C Richardson; Marc Peters-Golden Journal: FASEB J Date: 2012-05-29 Impact factor: 5.191
Authors: Vera Ivanova; Olga B Garbuzenko; Kenneth R Reuhl; David C Reimer; Vitaly P Pozharov; Tamara Minko Journal: Eur J Pharm Biopharm Date: 2012-12-08 Impact factor: 5.571